Drug details
Mounjaro (tirzepatide injection)
type of Antidiabetics, Glucagon-like Peptide-1 Agonists
Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
This drug may have the following side effects:
- nausea,
- sweating,
- dizziness,
- vomiting,
- nervousness,
- fever,
- shaking,
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- confusion,
- anxiety,
- irritability,
- fast heart rate,
- hunger,
- pain in the upper right side of your abdomen,
- pain spreading to your back or below the shoulder blade,
- yellowing of the skin and eyes (jaundice),
- clay-colored stools, and
- bloating of the abdomen
The following drugs are related to Mounjaro, either as a replacement or used together:
- Kazano (alogliptin and metformin hcl tablets)
- Brenzavvy (bexagliflozin tablets)
- Xigduo XR (dapagliflozin and metformin hcl extended-release tablets)
- Fiasp (insulin aspart injection for subcutaneous or intravenous use)
- Humalog (insulin lispro (human analog))
- Humalog 75-25 (75-25 insulin lispro suspension and 25 insulin lispro injection)
- Humalog Mix 50-50 (insulin lispro)
- NovoLog (insulin aspart [rdna origin] inj)
- NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin))
- Lantus (insulin glargine [rdna origin] injection)
- Semglee (insulin glargine injection)
- Toujeo (insulin glargine injection for subcutaneous use)
- NovoLog Mix 50/50 (50% insulin aspart protamine suspension and 50% insulin aspart injection)